Aaron Kobilis

Twice in the last two decades, U.S. heparin supply was threatened by serious recalls, production suspensions and near-critical shortages. Both times, Fresenius Kabi played a central role in protecting patient care.

Fresenius Kabi is doing More in America to enhance the supply reliability and availability of IV solutions on our freeflex^® IV bag platform.

Across the nation, critical oncology drugs are too often in short supply. While shortages are not exclusive to oncology medicines, delays in chemotherapy pose unique risks: patients need to get on and stay on specific drugs to treat their form of cancer.

Earlier this year, Fresenius Kabi hosted and sponsored the annual Angels for Change SummitONE conference. More than 150 healthcare leaders from across the pharmaceutical supply chain, along with government policy experts, came together for one purpose: to determine how to end drug shortages in this country.

Angels for Change, a global non-profit on a mission to end drug shortages, presented the organization’s 2024 Drug Shortage Guardian Award to Fresenius Kabi USA, a health care company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition.  Fresenius Kabi USA received the award in recognition of its exceptional teamwork and

To help improve safety and efficiency – and, in some cases, to discourage drug diversion – many hospitals in the U.S. are transitioning to ready-to-administer (RTA) drug presentations. That’s why Fresenius Kabi is doing More in America to expand the ready-to-administer options available to clinicians and caregivers – by offering prefilled, standard strength, single-patient delivery platforms in syringes and IV bags.